Therapeutic monoclonal antibody (mAb) inclusion in Multiple Myeloma treatment regimens offer patients significant improvements in clinical outcomes. Daratumumab and isatuximab are human mAb targeting CD38 used in Multiple Myeloma treatment regimens.
HYDRASHIFT removes therapeutic mAb interference on Immunofixation assays to allow for accurate interpretations.
HYDRASHIFT daratumumab and HYDRASHIFT isatuximab shift daratumumab and isatuximab interference on HYDRAGEL IF tests.
HYDRASHIFT reduces the risk of incorrect IF interpretation to improve therapy monitoring.
Fully integrated into IF protocol without sample pre-treatment for a standardized process compliant to IMWG guidelines.
Process compliant to IMWG guidelines to assess response to treatment in patient with Multiple Myeloma.
HYDRASHIFT is an immunofixation procedure performed on HYDRAGEL IF 2/4 gel and based on the creation of a mAB/ anti mAB immune complex shifts the mAB drug (daratumumab or isatuximab) into the alpha zone.
This complex is visible in the IgG and kappa immunofixation tracks. A negative HYDRASHIFT result demonstrates the absence of endogenous M-protein.
The limit of immune complex visualized is 0.3 g/L.
Large menu with high quality results on gel electrophoresis.
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with daratumumab.
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.